PIK3CD and acute lymphoblastic leukemia: As efforts to develop new pre-clinical and clinical inhibitors of the PI3K pathway are ongoing, few PI3K targeting drugs are under clinical evaluation for the treatment of acute lymphoblastic leukemia (Table 3).